Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Novo Nordisk forecast another year of double-digit sales growth for its two most popular drugs on Thursday and said it will boost U.S. supplies of Wegovy next year, as it battles to meet soaring ...

Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

Novo Nordisk has today launched its weight-loss injection Wegovy in Britain, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to ...

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...

The runaway success of Ozempic and Wegovy has turned 100-year old Novo Nordisk into Europe’s most valuable listed company, with a market capitalization bigger than Denmark’s domestic economy.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Novo Nordisk stated: “While 90% of patients taking Wegovy have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverage.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains ...